drugset
drugset / Trial / NCT00918450

Study Assessing the Safety and Efficacy of ABT-263 in Subjects With B-cell Chronic Lymphocytic Leukemia (CLL) Who Have Failed at Least One Prior Fludarabine-containing Regimen

NCT00918450 ↗

Phase 2 Withdrawn 150 enrolled Abbott Genentech, Inc. · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a Phase 2b, open-label, multicenter, global study assessing the safety and efficacy of ABT-263 in subjects with B-cell CLL who have failed at least one prior fludarabine-containing regimen.

Timeline

Start
2010-03
Primary completion
2012-12
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Navitoclax Small molecule — Oral

Indications

B-cell chronic lymphocytic leukemia